Lirilumab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Lirilumab
Monoclonal antibody
Type Whole antibody
Source Human
Target KIR2DL1/2/3
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
Formula C6452H9918N1698O2030S46
Molar mass 145.2 kg/mol

Lirilumab (INN) is a human monoclonal antibody designed for the treatment of cancer.[1][2] It binds to KIR2DL1/2L3.[3]

This drug was developed by Innate Pharma and is licensed to Bristol-Myers Squibb.

Clinical trials[edit]

A phase 2 clinical trial for acute myeloid leukemia (AML) was terminated early ("failed") in 2017.[4]

References[edit]

  1. ^ World Health Organization (2012). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107" (PDF). WHO Drug Information. 26 (2). 
  2. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Lirilumab, American Medical Association.
  3. ^ Romagné et al., Blood 2009 http://bloodjournal.hematologylibrary.org/content/114/13/2667.full.pdf Preclinical characterization of 1-7F9, a novel human anti–KIR receptor therapeutic antibody that augments natural killer–mediated killing of tumor cells
  4. ^ Innate Pharma Leukemia Candidate Lirilumab Fails Phase II Trial. Feb 2017